Zandelisib not checked

Kyowa Kirin Co., Ltd. · MEI Pharma, Inc. · ME-401

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
1 active
6 in total
Targets
 

What this is

How it works
Blocks PI3K, an enzyme that passes growth signals inside cells. Mostly used against cancer.-lisib: PI3K inhibitors WHO name stem
How it’s given
“In the first 2 cycles (1 cycle is 28 days), subjects will be administered 60 mg of ME-401 orally once a day on a continuous schedule (CS). After that, subjects will be administered 60 mg of ME-401 orally once a day for the first 7 days, followed by rest for 21 days on an intermittent schedule (IS).”In the company’s words, NCT04533581 on ClinicalTrials.gov
Tested for
Indolent B-cell Non-Hodgkin's Lymphoma
Main trialPhase 2
“The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of ME-401 in the treatment of Japanese participants with Relapsed or Refractory indolent B-Cell Non-Hodgkin's Lymphoma.”In the company’s words, NCT04533581 on ClinicalTrials.gov
Other names
ME-401

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials6

TrialPhaseCompletesWhat it tests
Phase 2Active, not recruiting 31 May 2028 Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma (NHL)
Phase 3Terminated 20 Mar 2023 Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)
Phase 2Withdrawn 15 Mar 2023 Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL
Phase 2Terminated 24 Mar 2023 Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL)
Phase 1Terminated 29 Mar 2023 A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma
Phase 1Completed 15 Jan 2025 Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Zandelisib

Following is part of Solo: you see every change to Zandelisib the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in